Understanding flucloxacillin prescribing trends and treatment non-response in UK primary care: a Clinical Practice Research Datalink (CPRD) study by Ronan, Lyons
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
Journal of Antimicrobial Chemotherapy
                                              
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa35441
_____________________________________________________________
 
Paper:
Francis, N., Hood, K., Lyons, R. & Butler, C. (2016).  Understanding flucloxacillin prescribing trends and treatment
non-response in UK primary care: a Clinical Practice Research Datalink (CPRD) study. Journal of Antimicrobial
Chemotherapy, 71(7), 2037-2046.
http://dx.doi.org/10.1093/jac/dkw084
 
 
 
 
 
 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License.
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/ 
 Understanding flucloxacillin prescribing trends and treatment
non-response in UK primary care: a Clinical Practice Research
Datalink (CPRD) study
Nick A. Francis1*, Kerenza Hood2, Ronan Lyons3 and Christopher C. Butler4
1Division of Population Medicine, School of Medicine, Cardiff University, 3rd Floor, Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK;
2Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, 7th Floor, Neuadd Meirionnydd, Heath Park, Cardiff
CF14 4YS, UK; 3Farr Institute, Swansea University Medical School, Singleton Park SA2 8PP, UK; 4Nuffield Department of Primary Care Health
Sciences, University of Oxford, New Radcliffe House, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6NW, UK
*Corresponding author. Tel: +029-20687133; Fax: +029-20687219; E-mail: francisna@cf.ac.uk
Received 12 November 2015; returned 12 January 2016; revised 23 February 2016; accepted 23 February 2016
Objectives: The volume of prescribed antibiotics is associated with antimicrobial resistance and, unlike most
other antibiotic classes, flucloxacillin prescribing has increased. We aimed to describe UK primary care flucloxa-
cillin prescribing and factors associated with subsequent antibiotic prescribing as a proxy for non-response.
Patients and methods: Clinical Practice Research Datalink patients with acute prescriptions for oral flucloxacillin
between January 2004 and December 2013, prescription details, associated Read codes and patient demo-
graphics were identified. Monthly prescribing rates were plotted and logistic regression identified factors
associated with having a subsequent antibiotic prescription within 28 days.
Results: 3031179 acute prescriptions for 1667431 patients were included. Average monthly prescription rates
increased from 4.74 prescriptions per 1000 patient-months in 2004 to 5.74 (increase of 21.1%) in 2013. The
highest prescribing rates and the largest increases in rates were seen in older adults (70+ years), but the overall
increase in prescribing was not accounted for by an ageing population. Prescribing 500 mg tablets/capsules
rather than 250 mg became more common. Children were frequently prescribed low doses and small volumes
(5 day course) and prescribing declined for children, including for impetigo. Only 4.2% of new prescriptions
involved co-prescription of another antibiotic. Age (,5 and ≥60 years), diagnosis of ‘cellulitis or abscess’ or no
associated code, and 500 mg dose were associated with a subsequent antibiotic prescription, which occurred
after 17.6% of first prescriptions.
Conclusions: There is a need to understand better the reasons for increased prescribing of flucloxacillin in primary
care, optimal dosing (and the need to co-prescribe other antibiotics) and the reasons why one in five patients are
prescribed a further antibiotic within 4 weeks.
Introduction
Flucloxacillin is themost common narrow-spectrum penicillinase-
resistant penicillin used in the UK. It is primarily used to treat infec-
tions caused by Staphylococcus aureus and, in the community,
use is almost exclusively for skin and soft-tissue infections
(SSTIs).1 Skin conditions are one of the most common reasons
for consulting in primary care and SSTIs are a common reason
for antibiotic prescribing in this setting.2,3
Antimicrobial resistance is one of the most pressing public
health concerns of our time,4 and resistance among S. aureus
to flucloxacillin and other penicillinase-resistant penicillins, in
the form of MRSA, is a key area of concern.5 However, while
many antibiotics are being prescribed less often, flucloxacillin
prescribing in UK primary care increased in the period up to
2006 overall6 and in adults7 and children.8 Higher volumes of anti-
biotic prescribing have been linked to greater levels of antibiotic
resistance, both at the ecological9 and individual patient10 levels.
Therefore, increasing levels of flucloxacillin prescribing, particu-
larly if the trend has continued during more recent years,
represent an important source of selection pressure for the devel-
opment of antibiotic resistance and, therefore, an important
threat to public health. However, recent trends have not been
published and there has been little in the way of fine-grained ana-
lyses to help understand possible reasons for the observed trends.
For example, some guidelines recommend co-treatment with
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phenoxymethylpenicillin (penicillin V) and flucloxacillin for cellu-
litis, particularly when severe or extensive;11,12 however, it is not
known how frequently primary care clinicians co-prescribe other
antibiotics with flucloxacillin. Furthermore, little is known about
the appropriateness of flucloxacillin prescribing. The diagnosis of
SSTIs can be problematic,13 the choice of antibiotic, route or
dose may be inappropriate, or the causative organisms may be
resistant. Treatment response is not routinely recorded in health-
care records, but the need for further antibiotics within the next
few weeks can be used as a proxy for treatment non-response.
Trends in prescribing, particularly when linked to diagnoses and
patient demographics, can be helpful for clinicians, policy makers
and researchers in assessing the appropriateness or not of prescrib-
ing. Therefore, we set out to: (i) describe trends in prescribing of flu-
cloxacillin by age, gender and indication; and (ii) describe patterns
of prescribing, including co-prescription of other antibiotics, further
antibiotic prescriptionswithin 28 days (as a proxy for non-response)
and factors associated with prescribing a further antibiotic as a
proxy measure for non-response to initial treatment.
Patients and methods
We analysed data from the Clinical Practice Research Datalink (CPRD) pri-
mary care dataset.14 CPRD developed from the General Practice Research
Database and includes one of the largest and best validated primary care
databases. The database contains data of over 20 years from over 650
general practices serving approximately 8% of the UK population. It
includes anonymous data on patient demographics, prescribed medica-
tions, medical (Read) codes, consultations and the practices contributing
to the database. CPRD conducts checks on data continuity and com-
pleteness and determines the date at which a practice as a whole is
assessed as providing data that are of an acceptable research standard.
In addition, patients are labelled as ‘acceptable’ for use in research by a
process that identifies and excludes patients with non-contiguous
follow-up or patients with poor data recording that raises suspicion as
to the validity of that patient record.
We identified all patients who had been prescribed any oral flucloxacil-
lin formulation during the 10 year period from 1 January 2004 to 31
December 2013 and were flagged as having data of acceptable quality.
Prescriptions (and any relatedmedial codes) were only included if: the pre-
scription date was after the date that the practice was assessed as being
‘up to standard’ (in terms of research quality data); after the date that the
patient registered; before the date that the patient died or transferred out
of the practice; and before the date of the last data collection from the
practice. Approximately 98% of the population of England and Wales
are registered with a general practitioner (GP) practice. Prescriptions for
flucloxacillin were identified based on product codes (please see the
Supplementary data available at JAC Online).
Prescriptions are entered on general practice computer systems as
either acute (single course) or repeat (a pre-set number of prescriptions
can be issued). For this analysis, only acute prescriptions were used, as
repeat prescriptions for flucloxacillin are uncommon and would only be
used for chronic conditions.
The number of prescriptions per study month was calculated and
divided by the average number of patients registered in the database for
that month. We then calculated monthly rates per 1000 registered
patients and adjusted these for the number of days in each month.
Monthly rates were plotted in a line graph and we used a simple linear
regression model, with month of year included as a dummy variable, to
calculate monthly (seasonal) effects as well as the underlying trend.
This analysis used a data extract from early 2014 and, therefore, some
encounters in the last couple of months of 2013 may have not been
included. Therefore, we used the linear regression model to predict
prescribing rates for December 2013. We then age-standardized the
rates using the population data of England and Wales from 2004.15
Each prescription was classified into one of four categories: 500 mg
tablets or capsules; 250 mg tablets or capsules; 250 mg/5 mL syrup or
suspension; and 125 mg/5 mL syrup or suspension. The number and pro-
portion falling into each category was calculated overall and by month,
and line graphs used to display changes over time. The recorded quantity
prescribed was identified. We excluded prescriptions where the quantity
was zero or so large that it was assessed as likely to be a coding error.
For tablets or capsules, we excluded quantities .112 (equivalent to
more than two tablets four times a day for 2 weeks) and for liquids,
where quantities are usually multiples of 100 mL, we excluded quantities
.2000 mL (equivalent to more than 20 mL four times a day for 25 days).
The quantity was used to estimate the length of the course and then
multiplied by the dose to calculate the total amount of antibiotic
prescribed.
Patient age (in years) at the date of prescription was calculated and
classified into one of seven age bands (0–4, 5–9, 10–19, 20–59, 60–
69, 70–79 and 80+ years) for age-specific rates and one of three age
bands (0–19, 20–59 and 60+ years) for age- and gender-specific rates.
Age- and age- and gender-specific rates were calculated as above, but
using age- and gender-specific monthly denominator counts.
In the UK, primary care clinicians use Read codes to record diagnoses,
symptoms, signs, procedures, etc. To describe the medical codes associated
with prescriptions for flucloxacillin, we identified Read codes that were linked
by consultation ID number. We searched for 2051 Read codes that could
potentially indicate an SSTI. As we only included consultations in which flu-
cloxacillin had been prescribed, we used an inclusive approach, for example,
‘breast lump’ as being indicative of a breast infection, ‘eczema’ indicative of
infected eczema and ‘dressing change’ indicative of a wound infection. We
included: 281 codes for SSTI diagnoses (cellulitis, abscess, impetigo, follicul-
itis, etc.); 42 codes for ingrowing nails, paronychia and other digital infec-
tions; 215 codes for breast, head and neck, bursitis, umbilicus and limb
infections; 884 codes for insect bites, other bites, traumatic wounds and
post-operativewounds; 524 codes for skin conditions thatmay become sec-
ondarily infected (eczema, seborrhoeic and contact dermatitis, psoriasis,
viral or fungal infections, skin ulcers, cysts, warts, naevi, blisters, etc.);
29 codes for non-specific ‘SSTI’, rash and ‘skin symptoms’; and 76 codes
for other skin conditions (erythrasma, phlebitis, thrombophlebitis, varicose
veins, pyoderma, acne, rosacea). These were then classified into one of
the following classifications: cellulitis or abscess, impetigo, boils/folliculitis,
infected finger/toe, infection of other skin region, infected trauma/wound,
secondary infection of skin lesion, non-specific SSTI and other skin infection.
We also searched for Read codes for respiratory tract infections, urinary tract
infections and osteomyelitis. Consultations with none of the above codes
were then classified as having, ‘no relevant code’ or no Read code. The
Read codes used are included in the Supplementary data available at JAC
Online. We then calculated the proportion of prescriptions that were classi-
fied into each categoryand the threemain subcategories foreachmajor cat-
egory. We also calculated monthly rates for each category of SSTI and
plotted these as a line graph.
We identified all antibiotic prescriptions that occurred over the 10 year
study period for all patients that had received one or more prescription for
flucloxacillin.We then identified all first prescriptions of flucloxacillin (those
that did not have another flucloxacillin prescription in the preceding
28 days) and then whether any additional antibiotics were co-prescribed
at the same time or in the following 28 days. Prescriptions are not directly
linked to a diagnosis in CPRD (but may be linked to Read codes via a con-
sultation ID number) and, therefore, we took a pragmatic approach of
including only prescriptions within the first 4 weeks as being likely to be
related to the same condition. Where subsequent antibiotics were pre-
scribed, we classified all subsequent antibiotic prescriptions that occurred
within 28 days of each other as part of the same ‘episode’. We then calcu-
lated the amount of time each patient was included in the database by
taking a start date as the later of 1 January 2004, the date they first
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registered with the practice or the date the practice was assessed as being
up to standard, and the end date as the earlier of 31 December 2013, the
date the patient transferred out of the practice, the date the patient died
or the last data collection date for the practice. Patients with,90 days of
observation were excluded and then the number of episodes per year of
observation was calculated and converted into number per 10 years.
In order to identify factors associated with receiving a subsequent pre-
scription of an antibiotic thatmight be used for an SSTI (oral penicillin,macro-
lide, tetracycline, cephalosporin, metronidazole, quinolone, clindamycin,
sodium fusidate or vancomycin) (as a proxy for potential treatment failure)
we used logistic regression. Patient age, gender, diagnostic category, dose
formulation, study year and an interaction between study year and formula-
tion (to determine whether changes in dose/formulation over time were
associated with having a subsequent antibiotic) were included as covariates.
This study was approved by the Independent Scientific Advisory
Committee (Ref: 14_096), the independent body that approves use of
CPRD data.
Results
We identified 1678403 patients who received 3114366 prescrip-
tions for flucloxacillin in 3110348 consultations over the 10 year
period. A total of 82399 (2.65%) prescriptions that were identified
as being ‘repeat prescriptions’ and a further 788 (0.03%) prescrip-
tions with dates that did not match the consultation date were
removed from further analysis, leaving 3031179 prescriptions
issued to 1667431 patients in 3029933 consultations.
Monthly prescription rates with amonthly linear regression line
are shown in Figure 1. The averagemonthly rates for each year are
presented in Table 1. Over the 10 year period from 2004 to 2013
prescribing for flucloxacillin increased by 21.1% [(5.7424.74)/
4.74]. There was significant seasonal variation with the highest
prescribing rates in the summer months and the lowest rates in
the winter, and an overall trend of increasing prescribing over
the study period. The relative influence of month of the year is
shown in the regression analysis in Table 2. The lowest prescription
rate was in December and the highest was in July, which had a
coefficient of 1.61 (95% CI: 1.35, 1.87), which equates to a 33%
increase compared with December [using the December 2008
rate (4.82) as the baseline].
Thereweremarked differences in prescribing rates by age band
(Figure 2). The highest prescribing rates were in those aged
70 years and over, with a gradual increase in prescribing rates
over the 10 year period in the 70–79 and 80+ age bands, a slight
increase in the 60–69 year olds and a slight reduction in the
5–9 year olds. Prescribing rates by gender were similar for children
(0–19) and older adults (60+), but for the 20–59 year age band
prescribing rates were consistently higher for women than men
(Figure 3).
The majority (87.2%) of prescriptions were of tablets or cap-
sules as opposed to suspensions or syrups. Over the 10 year per-
iod there was a substantial shift from prescribing predominantly
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Figure 1. Flucloxacillin prescription rate per month: 2004–13.
Table 1. Average monthly flucloxacillin prescribing rate by year
Year Prescribing rate (prescriptions per 1000 person-years)a
2004 4.74
2005 4.81
2006 5.12
2007 5.17
2008 5.33
2009 5.44
2010 5.54
2011 5.72
2012 5.83
2013 5.74
aAge-standardized to 2004 population of England and Wales.
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250 mg tablets or capsules to prescribing predominantly 500 mg
tablets or capsules (Figure 4). A total of 2688 (0.09%) prescrip-
tions were recoded asmissing for the analysis of quantity because
the quantities were over 112 (for tablets or capsules) or 2000 mL
(for liquids). Overall, 80.8% of all tablet/capsule prescriptions were
for 28 tablets/capsules, which equates to a 7 day course. Ten per-
cent were for ,28 and 9.2% were for .28. There was no signifi-
cant variation in the quantity prescribed across adult age groups
or by study year. As such, the shift in total amount of flucloxacillin
prescribed in each course increased for all adult age groups during
the period under study. For liquid preparations, 76.9% of
prescriptions were for 100 mL, which is equivalent to a 5 day
course of a 5 mL dose four times a day, with 1.5% being for
,100 mL and 21.6% being for .100 mL. The total amount of
antibiotic prescribed for children by age bands is shown in
Table 3. No change was seen over the 10 year period in the total
amount of antibiotic prescribed per course for younger children,
but a small increase was seen in 10–19 year olds.
Awide range of Read codeswere associatedwith consultations
in which flucloxacillin was prescribed. Consultations were classi-
fied into 1 of 12 broad categories (including ‘No code’) and
these, along with the most frequent diagnoses within each cat-
egory, are presented in Table 4. The most frequent category (‘No
relevant code’) represents consultations in which one or more
Read code was used, but there are no codes that give any indica-
tion of an infection or any other likely reason for prescribing flu-
cloxacillin. When this category is combined with those with no
code at all, one-third of all prescriptions were not associated
with any codes that indicated (or suggested) a diagnosis. The
most frequent diagnostic categories were secondary infection of
skin condition (10.2%), cellulitis or abscess (10.0%), non-specific
SSTI (9.5%) and infected trauma/wound (9.2%). A very small pro-
portion (0.3%) of prescriptions had codes for infections of other
systems (osteomyelitis, urinary tract infections or respiratory
tract infections) associated with them. Trends in the frequency
of SSTI categories over time are presented in Figure 5. The most
remarkable features are the marked seasonality for traumatic
(primarily insect bite) infections and the gradual decline in fluclox-
acillin prescribing for impetigo.
A total of 2888777 first (with no antibiotic prescription in the
preceding 28 days) prescriptions of flucloxacillin were identified in
1678183 patients; 3670 patients were removed because they
contributed ,90 days of data, leaving 2766006 episodes of
care (series of prescriptions with 28 days or less between them)
in 1674513 patients. A total of 486432 (17.6%) first prescriptions
Table 2. Linear regression of flucloxacillin prescribing rate on studymonth
controlling for month of year
Variable Coefficient (95% CI) P
Study month 0.01 (0.01, 0.01) 0.000
Month of the year
(reference: December)
January 0.18 (0.08, 0.44) 0.175
February 0.38 (0.12, 0.64) 0.004
March 0.53 (0.27, 0.79) 0.000
April 0.41 (0.15, 0.67) 0.002
May 0.61 (0.35, 0.87) 0.000
June 1.34 (1.08, 1.59) 0.000
July 1.61 (1.35, 1.87) 0.000
August 1.34 (1.08, 1.60) 0.000
September 1.26 (1.00, 1.52) 0.000
October 0.73 (0.47, 0.99) 0.000
November 0.55 (0.29, 0.81) 0.000
Constant 21.45 (22.36, 20.55) 0.002
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Figure 2. Flucloxacillin prescribing by age band: 2004–13. This figure appears in colour in the online version of JAC and in black and white in the print
version of JAC.
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were followed by a subsequent antibiotic prescription within
28 days and, of these, 126955 (4.6% of total) involved further
subsequent antibiotics, resulting in episodes that involved three
or more prescriptions. See Table 5. There was a median (IQR) of
2.0 (1.0, 3.0) episodes per patient per 10 years.
Only 115959 (4.2%) of 2766006 first prescriptions had
co-antibiotics (in addition to flucloxacillin) prescribed during the
same consultation. The most common co-antibiotics were penicillin
V (58.6%), amoxicillin (14.4%),metronidazole (12.6%), co-amoxiclav
(3.2%) and erythromycin (1.9%). The most frequently reported anti-
biotics prescribed at subsequent consultations (that involved pre-
scription of any antibiotic) were flucloxacillin (44.6%), co-amoxiclav
(10.2%), erythromycin (8.9%), amoxicillin (8.1%) and penicillin
V (6.7%).
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Figure 3. Flucloxacillin prescribing by gender for three age bands: 2004–13. This figure appears in colour in the online version of JAC and in black and
white in the print version of JAC.
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Younger (0–4 years) and older (60+) age (compared with the
reference category of 20–59 years), having a diagnosis of cellulitis
or abscess or having no Read code (compared with having a code
that did not indicate an infection) and being prescribed 500 mg
tablets (compared with 250 mg tablets) were all associated with
a 10% or more increase in the odds of having a subsequent anti-
biotic prescription within the next 28 days (Table 6). Having a diag-
nosis of boils/folliculitis or ‘infection at other site’ (mostly breast
infection or otitis externa) was associated with a 10% or more
reduction in the odds of having a subsequent antibiotic
Table 3. Total amount of flucloxacillin prescribed by age group (0–10 years)
Amount prescribed 1–1250 g, n (row %)
1251–2500 g,
n (row %)
2501–5000 g,
n (row %)
5001–7000 g,
n (row %) .7000 g, n (row %) Total, n
Equivalent to (upper band) 62.5 mg 4 times
a day for 5 days
125 mg 4 times a
day for 5 days
250 mg 4 times
a day for 5 days
250 mg 4 times
a day for 7 days
.250 mg 4 times
a day for 7 days
Age band (years)
0–1 1537 (3.3) 40661 (86.3) 4661 (9.9) 69 (0.2) 173 (0.4) 47101
2–3 237 (0.3) 54985 (79.7) 12840 (18.6) 361 (0.5) 595 (0.9) 69018
4–5 38 (0.1) 47622 (72.6) 15809 (24.1) 894 (1.4) 1237 (1.9) 65600
6–7 34 (0.1) 32605 (56.9) 20254 (35.4) 2177 (3.8) 2206 (3.9) 57276
8–10 69 (0.1) 25918 (33.9) 36003 (47.0) 9682 (12.7) 4866 (6.4) 76538
total 1915 (0.6) 201791 (64.0) 89567 (28.4) 13183 (4.2) 9077 (2.9) 315533
Table 4. Diagnostic classifications recorded with flucloxacillin prescribing
Coding category—n (%) Main subcategories (up to three) No. (% of total)
No relevant code—774082 (25.5) ‘patient reviewed’ 106458 (3.5)
‘telephone encounter’ 80530 (2.7)
‘had a chat to patient’ 34691 (1.1)
Secondary infection of skin conditions/lesions—309968 (10.2) infected eczema/dermatitis 103851 (3.4)
cysts, warts, naevi, blisters and other skin lesions 76682 (2.5)
infected cyst/blister 62697 (2.1)
Cellulitis or abscess—301805 (10.0) cellulitis 189359 (6.2)
cellulitis or abscess 59802 (2.0)
abscess 52644 (1.7)
Non-specific SSTI—286647 (9.5) SSTI not otherwise specified 192650 (6.4)
rash/skin symptoms 70106 (2.3)
Traumatic lesion/wound—277900 (9.2) wound/dressing 111312 (3.7)
insect bite 96227 (3.2)
post-operative infection 40137 (1.3)
Infected digit/nail—259261 (8.6) ingrowing nail 97173 (3.2)
paronychia 87811 (2.9)
infected toe/finger 74277 (2.5)
No code—244021 (8.1) 244021 (8.1)
Infection classified by site (other than digits)—223782 (7.4) breast infection 39901 (1.3)
otitis externa 35008 (1.2)
eye/eyelid infection 31667 (1.0)
Boils/folliculitis—170281 (5.6) furuncle/carbuncle 109287 (3.6)
folliculitis 60994 (2.0)
Impetigo—126638 (4.2) impetigo 126638 (4.2)
Other skin infection—49026 (1.6) superficial phlebitis 14849 (0.5)
pustules/septic spots 13781 (0.5)
superficial lump/swelling 7890 (0.3)
Other infection—7768 (0.3) respiratory 6784 (0.2)
urinary 590 (,0.1)
osteomyelitis 394 (,0.1)
Total: 3031179 (100)
Francis et al.
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prescription, when compared with having no relevant diagnostic
code. There was no significant (in terms of size of effect) associ-
ation with time (year) and no significant interaction between
dose and time (year).
Discussion
The prescription rate for flucloxacillin in primary care in the UK
increased by 21.1% between 2004 and 2013, with marked peaks
in the summer. Over the same period, there was a marked shift
toward prescribing higher-dose (500 mg tablets) over low-dose
(250 mg tablets) flucloxacillin. The highest prescribing rates and
the largest increases in rates were seen in older adults (70+).
There were few differences by gender. The quantity/duration of
antibiotics prescribed (typically 7 days for tablets and 5 days for
liquid) did not change significantly and, therefore, the increasing
use of higher-dose tablets led to an increase in the average total
amount of antibiotic prescribed between 2004 and 2013 for adults.
Many children were prescribed lower doses than recommended for
their age (for example, one-third of 8–10 year olds were prescribed
the equivalent of 125 mg 4 times a day for 5 days or less). Cellulitis
or abscess, secondary infection of skin conditions and infected
trauma/wound were the most prevalent diagnostic categories.
However, over a third of prescriptions had no associated relevant
medical diagnostic code and a further 10% were associated with
a non-specific SSTI code. Most (82.4%) new prescriptions for flu-
cloxacillin were not followed by an antibiotic prescription within
the next 28 days. Therewas amedian of 2 (IQR 1, 3) episodes (clus-
ters of antibiotic prescriptions within 28 days of each other that
startedwith a prescription of flucloxacillin) per 10 years per patient.
Being ,5 or ≥60 years, having a diagnostic code for cellulitis or
abscess or no diagnostic code, and being prescribed higher-dose
flucloxacillin, were all associated with an increased odds of being
prescribed an antibiotic in the 28 days following an initial flucloxa-
cillin prescription. Only 4.2% of first prescriptions of flucloxacillin
had another antibiotic prescribed at the same time and 58.6% of
these were penicillin V.
This study used a large, well-validated database with research
quality data.16 By using data going back to 2004 we were able to
examine trends over time and, by using such a large dataset, we
were able to describe precisely the rates bymonth (and, therefore,
describe the seasonality of use) and by important subgroups.
Prescriptions in UK general practice are almost universally gener-
ated via the computer and, therefore, recording of prescribing
data is very accurate. However, it is possible that some prescrip-
tions, particularly those generated during home visits, will not
be included. Home visits are a small proportion of the workload,
particularly for a condition that does not often incapacitate
(SSTIs), but it is possible that housebound patients, who are at
risk of cellulitis, are under-represented.
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Figure 5. Flucloxacillin prescribing bydiagnostic category: 2004–13. This figure appears in colour in the online version of JACand in black andwhite in the
print version of JAC.
Table 5. Number of prescriptions per episode of care
Number of prescriptions
in episode
Number of
episodes
Proportion of
episodes (%)
1 2279574 82.4
2 359477 13.0
3 83013 3.0
4+ 43942 1.6
Total 2766006 100
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The main weakness of this study is that prescriptions are not
directly linked to diagnosis in CPRD. Linking of diagnostic codes
can only be achieved at the level of the consultation (i.e. Read
codes entered during the same consultation in which a prescrip-
tion is issued are likely to be linked). However, we found that even
at the consultation level a high proportion of prescriptions had no
associated diagnostic codes. There are also few data available to
measure the accuracy of the diagnostic codes used and, given the
large number of codes within the Read system, there will inevit-
ably be variations in coding practices between GPs. Fortunately,
flucloxacillin is an antibiotic that is only indicated for infections
likely to be caused by S. aureus and, in UK primary care, this is
almost exclusively SSTIs. Therefore, we can have confidence in
the overall levels of prescribing being robust, but the subdivision
by diagnoses may need to be treated with caution. In our analysis
of subsequent prescribing, we identified prescriptions for any anti-
biotic that could be used for SSTI and did not limit inclusion to
those that were associated with an SSTI code. It is possible that
some of these prescriptions were for alternative (new) diagnoses,
such as respiratory tract infections; however, we restricted the
follow-up period to 4 weeks and found that the most commonly
prescribed subsequent antibiotic was also flucloxacillin. Therefore,
we believe that we are predominantly identifying subsequent pre-
scribing for SSTIs.
Previous analyses of flucloxacillin prescribing in primary care have
shown rates increasing up to 20066–8 and we were able to demon-
strate that this trend continued up to the end of 2013 and that
increases were primarily in older adults. We used age-specific popu-
lation denominators and the rates have been age-standardized to
the 2004 population of England and Wales, and so the increases
do not simply relate to an ageing population. However, the changes
in population demographics, with significant ongoing increases in
the proportion of the population that are older, do make these
data particularly concerning and worthy of further investigation.
Table 6. Factors associated with a subsequent antibiotic prescription within 28 days
OR 95% CI (lower) 95% CI (upper)
Age band (years)
0–4 1.27 1.24 1.30
5–9 0.91 0.88 0.93
10–19 0.93 0.92 0.94
20–59 (reference) 1
60–69 1.37 1.35 1.38
70–79 1.57 1.55 1.58
80+ 1.67 1.66 1.69
Gender
male (reference) 1
female 1.04 1.03 1.04
Diagnostic category
no SSTI code (reference) 1
cellulitis or abscess 1.32 1.31 1.34
impetigo 1.08 1.06 1.10
boils/folliculitis 0.90 0.89 0.91
infected digit/nail 0.95 0.94 0.96
infection classified by site (other than digits) 0.88 0.87 0.89
traumatic lesion/wound 0.91 0.89 0.92
secondary infection of skin lesion 1.00 0.99 1.01
non-specific SSTI 0.95 0.94 0.96
other skin infection 0.99 0.96 1.01
no code 1.28 1.27 1.30
Dose
500 mg tablets 1.29 1.27 1.31
250 mg tablets (reference) 1
suspension 1.00 0.97 1.02
Year (continuous) 1.00 1.00 1.00
Dose×year interaction
500 mg 1.00 1.00 1.00
250 mg (reference) 1
liquid 1.01 1.00 1.01
Constant 0.17 0.15 0.16
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One question is whether the increase in flucloxacillin prescrib-
ing is caused by an increase in the incidence of consultations for
SSTI or if it relates to a reduction in the threshold for prescribing.
We recently identified SSTIs as a common infection and a com-
mon reason for antibiotic prescription in older adults in care
homes.17 However, data on how the incidence of SSTIs in this
age group has changed over time is somewhat conflicting.
Fleming et al.7 reported reductions in the incidence of skin infec-
tions in primary care for both adults and children between 1999
and 2005, but did not look specifically at older adults. Hayward
et al.,6 on the other hand, used Hospital Episode Statistics data
to explore trends in hospital admissions for community-onset
staphylococcal diseases and found an increase between 1989–
90 and 2003–04, with the highest rates, and greatest increases,
in older adults.
Although any trend toward increased antibiotic prescribing is
potentially concerning, the implications of increasing flucloxacillin
prescribing on antimicrobial resistance (in the form of MRSA) are
unclear. A recent study of the prevalence of MRSA in commensals
identified from the anterior nares of individuals in the community
found low levels in all nine European countries studied (including
the UK).18
We were not able to identify any other studies that highlighted
the shift from prescribing lower-dose to higher-dose flucloxacillin
over the past decade. The higher dose is certainly recommended
for cellulitis or other infections where group A streptococci are
the likely causative organisms. However, there remains little empir-
ical evidence to guide the dose or duration of treatment. The use of
lower than recommended unit doses for flucloxacillin in children
has been previously described,19 but we took this further by identi-
fying that most children are prescribed only enough for 5 days. As
with adults, there is little empirical evidence supporting an optimal
dose or duration. However, our datamake it apparent that children
are frequently prescribed low doses and short courses.
We found that nearly one in five patients who are prescribed a
course of flucloxacillin are prescribed a subsequent course of anti-
biotics within 4 weeks, suggesting that treatment failuremay be a
significant problem. Currie et al.3 reported a treatment failure rate
for SSTIs, using a similar approach, but identifying consultations
where any antibiotic was associated with a diagnosis of SSTI
(rather than flucloxacillin prescribing), of 12.8%. However, the
diagnosis of bacterial infection is not always straightforward in
primary care and prescribing a subsequent antibiotic is not neces-
sarily an indication that the first antibiotic ‘failed’. For example, in
our study subsequent antibiotic prescribing may have been for
another condition or for colonized skin ulcers, eczema flares or
hidradenitis suppurativa, and may not be an indication that the
first antibiotic ‘failed’. Nevertheless, most antibiotic treatment is
intended to be delivered as a single course and, therefore, our
finding that 17.6% received a subsequent course is of concern.
We found that being prescribed a higher dose of flucloxacillin
increased the risk of being prescribed a subsequent antibiotic.
This probably represents confounding by indication, with those
having more severe infections prescribed higher doses and thus
being more likely to re-consult. Our finding that children were
less likely (than adults) to require a subsequent course, despite
often receiving doses that are below guideline recommendations,
suggests that either dosing guidelines need revisiting or that
many of these initial prescriptions were unnecessary. Resistance
to flucloxacillin may be a reason for the high rate of further
prescriptions; however, MRSA prevalence in commensal organ-
isms in the community is relatively low in the UK.18 Diagnosis of
skin infections has been shown to be problematic,13 and misdiag-
nosis may also be a contributing factor.
Seasonal variation has been previously described in both
the incidence of impetigo20 and hospital admissions for non-
necrotizing cellulitis,21 and Fleming et al.7 have previously
shown increased flucloxacillin prescribing in the third quarter.
However, we have provided a more detailed analysis and been
able to show that prescribing peaks in July and that seasonal vari-
ation is more pronounced for some diagnostic categories
(infected traumatic lesions, cellulitis and non-specific SSTI) than
for others (impetigo and ‘other SSTI’).
Cellulitis is themain serious SSTI and, therefore, it is not surpris-
ing that cellulitis or abscess was identified as one of the most
common diagnostic categories. However, we found that many
prescriptions were associated with other codes or not associated
with any useful code. A previous study of indications for antibiotic
prescribing in primary care identified ‘skin’, ‘other’, ‘abscess/boil’ and
‘impetigo’ as the most common categories.1 It is difficult to make
direct comparisons due to differences in the way conditions were
classified, but we found that ‘boils’ and ‘impetigo’ were uncommon
diagnoses associated with flucloxacillin prescribing and that ‘no
relevant code’ and ‘secondary infection of skin conditions/lesions’
were the most common categories. Part of the explanation for
the differences lies in the complexities of Read coding; some Read
codes are for ‘cellulitis or abscess’ and, therefore, as it was impos-
sible to disentangle these diagnoses completely, we grouped them
together. There is clearly an important need to improve coding in
primary care medical records. NHS funders should work closely
with electronic medical record suppliers to optimize their systems
to make it easier to apply codes accurately, and primary care staff
should be trained and incentivized to codemore accurately. Finally,
the UK should consider moving away from the Read code system,
which is repetitive and allows for vague and unhelpful coding, to a
more standardized and universally accepted coding system such as
the International Classification of Primary Care.
Previous research has highlighted higher levels of antibiotic
prescribing (particularly flucloxacillin) in patients identified as hav-
ing chronic wounds.22 While we did not specifically identify this
group, codes associated with wounds/dressings accounted for
only 3.7% of prescribing in our study, suggesting that while high
levels of prescribing may have important implications for the indi-
viduals involved, chronic wounds do not seem to be a major con-
tributor to overall levels of acute prescribing for flucloxacillin.
S. aureus and group A streptococci are both important causes
of skin infections and guidelines sometimes recommend using
flucloxacillin to cover the Staphylococcus and penicillin V for the
streptococci.11 We found that co-prescribing occurred in only a
small minority of consultations and we are not aware of any
other evidence on the frequency of co-prescribing penicillin V
with flucloxacillin.
Our findings highlight a need to understand better the reasons
for the ongoing increase in prescribing of flucloxacillin in UK primary
care. Althoughwe identified older age anddiagnosis of cellulitis, and
not a younger age and diagnosis of impetigo, as areas to focus on,
problemswith diagnostic coding limited ourability to drawfirmcon-
clusions. Prospective observational studies or analyses of routine
data where the diagnosis is confirmed (by contacting participating
clinicians or through an analysis of the ‘free text’) could provide
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greater clarity. It is unclear how generalizable our results are to
other settings (secondary care and other countries) and there are
limited data on MRSA. There is also a need for trials to explore the
optimal use of oral antibiotics in the management of SSTIs, includ-
ing optimal dose and duration and the role of co-prescription of
penicillin V, or other antibiotics, with flucloxacillin. Finally, there is
a need to understand why the prescribing of further antibiotics
within 4 weeks of an initial prescription of flucloxacillin is so preva-
lent. Suboptimal dosing or incorrect choice of antibiotic may play a
role, but misdiagnosis of other inflammatory skin conditions as
infection could also be a reason. Therefore, there is a need to evalu-
ate (and seek to improve) the diagnostic accuracy of the clinical
diagnosis of cellulitis in primary care.
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